
Dec 23 (Reuters) - A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
The individual died on December 14 after suffering a stroke followed by a brain hemorrhage, according to the European Haemophilia Consortium, a patient support group.
The patient was enrolled in a study that was testing Hympavzi in patients with hemophilia A or B with or without inhibitors.
"Pfizer, together with the trial investigator and the independent external Data Monitoring Committee, are actively gathering information to better understand the complex, multi-factorial circumstances surrounding this occurrence," the company said in a statement.
The therapy, a once-a-week injection, gained U.S. approval last year to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older by targeting blood-clotting proteins.
Pfizer does not anticipate any impact to safety for patients treated with the drug based on its current knowledge and the overall clinical data collected to date, the company said.
People with hemophilia have a defect in a gene that regulates the production of proteins called clotting factors, causing spontaneous and severe bleeding following injuries or surgery.
Earlier this year, Pfizer said it would halt global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
Beqvez, a one-time therapy, was approved in the U.S. for the treatment of adults with moderate to severe hemophilia B.
(Reporting by Sneha S K in Bengaluru; Editing by Anil D'Silva)
latest_posts
- 1
Vote In favor of Your Favored Sort Of Bevarage - 2
Figurine of a woman and a goose offers peek at prehistoric beliefs - 3
Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2 - 4
Senegal president signs tough new anti-LGBT law doubling jail terms - 5
Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
AfD faction in western Germany ousts councilman for firebrand speech
Most loved Web-based feature: Which Stage Do You Like
Vote In favor of Your Favored Sort Of Dress
Shrewd Home Gadgets to Save Energy
Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
25 of the world’s best sandwiches
Shah Capital pushes for Novavax sale, warns of proxy fight
How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker













